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Dear Editor,  
 
We welcome the work of Rishu and colleagues [1] in tracking the timelines to 
initiation of outbreak and pandemic observational research. Through this work 
they highlight the significant challenges in being prepared with a clinical 
research response for the next pandemic. Pandemics are unpredictable but also 
recurrent. Recent experience of Ebola and Zika outbreaks highlight the 
devastating impact these outbreaks have on the health, economy and security of 
communities for generations to come.  
 
An effective clinical research response for an outbreak relies on expedience, co-
ordination, co-operation and adaptability; and compels a shift in the current 
paradigm of research delivery [2]. We have been encouraged by noting shifts 
along these lines in areas of research regulation in Europe. For example, many 
ethics committees in Europe now facilitate expedited review of clinical studies. 
These channels could be accessed in the event of an outbreak. A new regulation 
governing intervention studies conducted in Europe [3], effective by October 
2018, makes provision for a new category of research, recognizing that not all 
intervention research presents the same level of risk to participants. This may 
facilitate comparative effectiveness research during an outbreak. New 
approaches to obtaining informed consent may be suited to certain kinds of 
pandemic research [4]   
 
However, there remain many bottlenecks preventing the expedient setup and 
conduct of clinical studies during an outbreak. Many of the delays to initiation of 
research arise from human behavior factors: reviewing protocols, agreeing data 
sharing arrangements and contract agreements. While regulatory mechanisms 
are important and necessary to ensure integrity of research conduct, we need 
new ways of thinking about how to enact these protections to expedite research 
during a pandemic outbreak. It is vital that the public, as a major stakeholder, 
have a voice in this debate in how to optimize our research response. It is 
essential that we are able to generate the scientific advances and innovations 
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